Wai Conrad 4

What Happened
Wai Conrad, listed as CEO (Counterpart Health) and an insider of Clover Health Investments, sold 220,426 shares on May 28, 2026. The filing reports an average price of $3.99 per share for total gross proceeds of about $879,500. The sale was executed as open-market transactions and reported on Form 4 as a disposal (code S).

Key Details

• Transaction date: 2026-05-28.
• Price: Average $3.99; actual trade prices ranged from $3.92 to $4.04 (sales occurred in multiple transactions).
• Shares sold: 220,426; proceeds ≈ $879,500.
• Transaction type: Open-market sale under a Rule 10b5-1 trading plan (adopted March 3, 2025) — footnote F1.
• Ownership after transaction: Not specified in the provided filing.
• Other footnote: F2 notes shares held in trust for the reporting person’s family, where the reporting person is a co-trustee.
• Filing timeliness: Period of report and filing date are both 2026-05-28; no late filing indicated.

Context
The sale was made under a pre-established Rule 10b5-1 plan, which typically schedules trades in advance and is commonly used by insiders to avoid appearance of trading on nonpublic information. Sales under 10b5-1 plans are often routine financial or diversification actions and do not by themselves indicate management’s view of the company’s prospects. Retail investors may view insider purchases as more informative of confidence than scheduled sales like this one.